Acadia Pharmaceuticals Stock
Acadia Pharmaceuticals Stock
The Acadia Pharmaceuticals stock is trending slightly upwards today, with an increase of €0.050 (0.250%) compared to yesterday's price.
With 32 Buy predictions and 1 Sell predictions Acadia Pharmaceuticals is one of the favorites of our community.
As a result the target price of 27 € shows a positive potential of 35.2% compared to the current price of 19.97 € for Acadia Pharmaceuticals.
For the coming years our community has positive and negative things to say abot the Acadia Pharmaceuticals stock. Criterium "Worthwhile Investment for the next years" gathered the most positive votes but regarding "EBIT growth" there were negative voices in the community.
Pros and Cons of Acadia Pharmaceuticals in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
M***** P*******
?
G***** c******* t* c**********
Cons
?
C******** o* t** e**********
?
B****
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Acadia Pharmaceuticals vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Acadia Pharmaceuticals | 0.250% | -7.306% | -10.713% | 5.789% | -14.249% | 16.450% | -51.456% |
| Ironwood Pharmaceuticals | -1.080% | -7.463% | -4.124% | 82.353% | 39.850% | -64.538% | -55.976% |
| Novocure Ltd | 1.400% | -17.078% | -27.095% | -63.140% | -24.393% | -90.175% | -94.120% |
| Iovance Biotherapeutics Inc. | 5.730% | -8.500% | -3.740% | -65.731% | -15.367% | -72.864% | -95.122% |
Comments
ACADIA Pharmaceuticals (NASDAQ:ACAD) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $37.00 price target on the stock.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating.
Show more
Ratings data for ACAD provided by MarketBeat
ACADIA Pharmaceuticals (NASDAQ:ACAD) was given a new $40.00 price target on by analysts at UBS Group AG. They now have a "buy" rating on the stock.
Show more
Ratings data for ACAD provided by MarketBeat